Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value

Related Content

Actelion's Uptravi Approval To Shake Up Market

Dec 23 2015

Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing

Jan 25 2017

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Aug 22 2016

Will Sanofi Overpay For Actelion Innovation Or, Like J&J, Also Walk Away?

Dec 14 2016

Was Sanofi’s Offer One That Actelion Could Refuse? J&J Back At Bargaining Table

Dec 22 2016

Related Companies

Johnson & Johnson

Actelion Pharmaceuticals Ltd.

Sanofi

Seragon Pharmaceuticals

Genentech, Inc.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Pfizer Inc.

Bayer AG

Gilead Sciences, Inc.

United Therapeutics Corporation

Takeda Pharmaceutical Co. Ltd.

Baxalta Incorporated

Teva Pharmaceutical Industries Ltd.

Allergan plc

Medivation, Inc.

Additional Topics

M & A Deals Business Strategies Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window